Charles River Laboratories Non-Controlling Interest 2010-2025 | CRL

Charles River Laboratories non-controlling interest for the twelve months ending March 31, 2025 was $0.002B, a 69.36% decline year-over-year.

  • Charles River Laboratories annual non-controlling interest for 2024 was $0.003B, a 46.26% decline from 2023.
  • Charles River Laboratories annual non-controlling interest for 2023 was $0.006B, a 9.97% decline from 2022.
  • Charles River Laboratories annual non-controlling interest for 2022 was $0.006B, a 18.75% decline from 2021.

Charles River Laboratories Non-Controlling Interest 2010-2025 | CRL

  • Charles River Laboratories annual non-controlling interest for 2024 was $0.003B, a 46.26% decline from 2023.
  • Charles River Laboratories annual non-controlling interest for 2023 was $0.006B, a 9.97% decline from 2022.
  • Charles River Laboratories annual non-controlling interest for 2022 was $0.006B, a 18.75% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$147.3B
CVS Health (CVS)$83.1B
Elevance Health (ELV)$65.9B
Cencora (COR)$56B
DiDi Global (DIDIY)$26.7B
Labcorp Holdings (LH)$22.4B
Natera (NTRA)$21.9B
BioMerieux (BMXMF)$17.2B
EUROFINS SCIENT (ERFSF)$15.3B
ICON (ICLR)$13.7B
CochLear (CHEOY)$13.3B
Medpace Holdings (MEDP)$12.9B
Solventum (SOLV)$12.5B
Viatris (VTRS)$11.8B
Revvity (RVTY)$10.2B
Sonic Healthcare (SKHHY)$9.2B
Avantor (AVTR)$8.6B
Caris Life Sciences,�Inc (CAI)$8.3B
HealthEquity (HQY)$8B
Bausch + Lomb (BLCO)$4.9B
Sotera Health (SHC)$4.2B
Amplifon S.p.A (AMFPF)$3.9B
BrightSpring Health Services (BTSG)$3.8B
GeneDx Holdings (WGS)$3.3B
Surgery Partners (SGRY)$2.9B
Alignment Healthcare (ALHC)$2.9B
Concentras Parent (CON)$2.9B
Organon (OGN)$2.4B
Premier (PINC)$2B
Progyny (PGNY)$1.9B